Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics

NEXT STORY
Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision Medicine Informatics
PREV STORY
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) ...

author_avatar
NASDAQ Market News

Three New Articles Focus on COVID-19: Diagnosis and Risk Factors

author_avatar
NASDAQ Market News